Dr. Rovin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
543 Taylor Ave
Columbus, OH 43203Phone+1 614-293-4837Fax+1 614-293-3125
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Nephrology, 1989 - 1989- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1983 - 1986
University of Illinois College of MedicineClass of 1983
Certifications & Licensure
OH State Medical License 1990 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (ASNF) American Society of Nephrology
Clinical Trials
- Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Start of enrollment: 2009 Feb 01
- MEmbranous Nephropathy Trial Of Rituximab Start of enrollment: 2011 Nov 01
- GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases Start of enrollment: 2011 May 01
- Join now to see all
Publications & Presentations
PubMed
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.Richard A Furie, Brad H Rovin, Jay P Garg, Mittermayer B Santiago, Gustavo Aroca-Martínez
The New England Journal of Medicine. 2025-02-07 - 1 citationsAlternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.Vlado Perkovic, Jonathan Barratt, Brad Rovin, Naoki Kashihara, Bart Maes
The New England Journal of Medicine. 2025-02-06 - Comment on: Renal Arteriosclerosis in kidney biopsies associated with higher 10-year atherosclerotic cardiovascular disease in lupus nephritis: Reply.Shivani Garg, Brad Rovin, Amish N Raval, Christie M Bartels
Rheumatology. 2025-02-04
Journal Articles
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus NephritisRichard Furie, Brad H Rovin, The New England Journal of Medicine
- A Randomized, Controlled Double-Blind Study Comparing the Efficacy and Safety of Dose-Ranging Voclosporin with Placebo in Achieving Remission in Patients with Active L...Brad H Rovin, William F Pendergraft, Kidney International
- Peripheral Blood B Cell Depletion After Rituximab and Complete Response in Lupus NephritisMatthew D Cascino, Jay Garg, Paul Brunetta, Tamiko R Katsumoto, Paul Brakeman, Brad Rovin, Leonard Dragone, Richard John Looney, Journal of the American Society of Nephrology
Lectures
- Case Studies in Glomerular DiseaseAmerican Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/9/2019
- A Prospective Observational Cohort Study Highlights Kidney Biopsy Findings of Lupus Nephritis Patients in Remission Who Flare Following Withdrawal of Maintenance TherapyAmerican Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/7/2019
Other
- A Prospective Observational Cohort Study Highlights Kidney Biopsy Findings of Lupus Nephritis Patients in Remission Who Flare Following Withdrawal of Maintenance TherapyBrad Rovin, MD, Kidney International
https://www.doximity.com/articles/f57e0281-b555-4e34-9cc9-02fdf46f5ce7
UpToDate, Wolters Kluwer Health - 2013-01-03 - A Prospective Observational Cohort Study Highlights Kidney Biopsy Findings of Lupus Nephritis Patients in Remission Who Flare Following Withdrawal of Maintenance TherapyBrad Rovin, MD, Kidney International
https://www.doximity.com/articles/f57e0281-b555-4e34-9cc9-02fdf46f5ce7
UpToDate, Wolters Kluwer Health - 2013-01-24 - A Prospective Observational Cohort Study Highlights Kidney Biopsy Findings of Lupus Nephritis Patients in Remission Who Flare Following Withdrawal of Maintenance TherapyBrad Rovin, MD, Kidney International
https://www.doximity.com/articles/f57e0281-b555-4e34-9cc9-02fdf46f5ce7
UpToDate, Wolters Kluwer Health - 2013-03-06 - Join now to see all
Press Mentions
Positive Phase III Results for Roche’s Gazyva/Gazyvaro Show Superiority to Standard Therapy Alone in People with Lupus NephritisSeptember 26th, 2024- Positive Phase III Results for Roche’s Gazyva/Gazyvaro Show Superiority to Standard Therapy Alone in People with Lupus NephritisSeptember 26th, 2024
- Sparsentan Receives Full FDA Approval for Treatment of IgANSeptember 6th, 2024
- Join now to see all
Grant Support
- Forecasters Of Futute And Progressive CDK In Patients With Microvascular GlomerulNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
- Modeling SLE Nephritis Through Urine MCP-1National Institute Of Diabetes And Digestive And Kidney Diseases2008–2010
- Protein Phenotyping Of SLE Nephritis Flare CycleNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2009
- Proteomic And MRNA Profiling Of Urine And Urine SedimentNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
- Chemokine Regulation In Human SLE NephritisNational Institute Of Diabetes And Digestive And Kidney Diseases2001–2002
- Chemokine Regulation In Immune Complex Renal DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2001
- Effect Of H5g1.1 Monoclonal Antibody On Reduction Of Proteinuria In PatientsNational Center For Research Resources2000
- Mesangial Regulation Of Glomerular Leukocyte TrafficNational Institute Of Diabetes And Digestive And Kidney Diseases1993–1997
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
